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Abstract
PURPOSE: We report on a novel preclinical pancreatic cancer research model that uses bioluminescence imaging
(BLI)–guided irradiation of orthotopic xenograft tumors, sparing of surrounding normal tissues, and quantitative,
noninvasive longitudinal assessment of treatment response. MATERIALS AND METHODS: Luciferase-expressing
MiaPaCa-2 pancreatic carcinoma cells were orthotopically injected in nude mice. BLI was compared to pathologic
tumor volume, and photon emission was assessed over time. BLI was correlated to positron emission tomography
(PET)/computed tomography (CT) to estimate tumor dimensions. BLI and cone-beam CT (CBCT) were used to com-
pare tumor centroid location and estimate setup error. BLI and CBCT fusion was performed to guide irradiation of
tumors using the small animal radiation research platform (SARRP). DNA damage was assessed by γ-H2Ax stain-
ing. BLI was used to longitudinally monitor treatment response. RESULTS: Bioluminescence predicted tumor
volume (R = 0.8984) and increased linearly as a function of time up to a 10-fold increase in tumor burden. BLI cor-
related with PET/CT and necropsy specimen in size (P < .05). Two-dimensional BLI centroid accuracy was 3.5 mm
relative to CBCT. BLI-guided irradiated pancreatic tumors stained positively for γ-H2Ax, whereas surrounding normal
tissues were spared. Longitudinal assessment of irradiated tumors with BLI revealed significant tumor growth delay
of 20 days relative to controls. CONCLUSIONS:We have successfully applied the SARRP to a bioluminescent, ortho-
topic preclinical pancreas cancer model to noninvasively: 1) allow the identification of tumor burden before therapy,
2) facilitate image-guided focal radiation therapy, and 3) allow normalization of tumor burden and longitudinal
assessment of treatment response.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer-related deaths
in the United States with an overall relative survival rate of 5% at
5 years [1]. Although most clinical trials have substantiated the
modest clinical benefit of gemcitabine-based chemotherapy, the role
of radiation in the adjuvant and definitive setting remains controver-
sial [2,3]. Unfortunately, most randomized trials studying the addi-
tion of molecular targeting agents, gene therapy, and immunotherapy
have also failed to showmeaningful benefit [4]. As a result, clinical trials
with a higher likelihood for success need to be designed using more
effective multimodal treatment strategies. Whereas preclinical animal
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research is integral to the development of such therapies, available
models are far from optimal. Technological advances made in human
conformal radiation treatment have significantly outpaced those for
laboratory animal research, which is often nonlocalized, single-beam
irradiation of large fields due to lack of accurate targeting and delivery.
Recognizing the pressing need to bridge this translational gap for radi-
ation research, several groups have initiated development of small ani-
mal irradiators [5,6]. Our group has developed a small animal radiation
research platform (SARRP) incorporating: 1) a gantry and robotic stage
that supports isocentric and noncoplanar conformal irradiation and 2)
on-board cone-beam CT (CBCT) guidance to facilitate coregistration
with other imaging and accurate repositioning for fractionated therapy
[7]. While suitable for superficial targets and those with adequate radio-
graphic contrast, such as in the lung or where bony landmarks can be
used as a surrogate, CBCT is not optimal to precisely localize orthotopic,
intrathoracic, and intra-abdominal tumors owing to the lack of soft
tissue contrast and functional tumor imaging. Similar to clinical appli-
cations, a complementary soft tissue imaging modality could help facil-
itate precise delineation of the tumor and its margins. BLI has emerged
as a noninvasive means of longitudinal in vivo assessment of tumors, as
well as response to therapy in preclinical models [8]. Although BLI has
become an integral component of preclinical tumor models, its appli-
cation to date with radiation has been limited [9]. Biologically relevant
tumor models are also an essential component of preclinical studies.
Subcutaneous xenograft models are the most commonly used modality
for preclinical experimental therapeutics because they represent a
convenient platform for monitoring tumor growth and response to
therapy. However, they are less than ideal for translational research
on pancreatic tumors secondary to their inability to faithfully recapitu-
late the tumor microenvironment and locally invasive and metastatic
nature of the disease [10].
Herein, we report on a novel approach to preclinical pancreatic can-
cer radiation research that allows BLI-guided irradiation of orthotopic
xenograft tumors, sparing of surrounding normal tissues and quantita-
tive, noninvasive assessment of treatment response. This unique trans-
lational model is currently being used to successfully investigate the
mechanisms of action and efficacy of chemotherapeutic and targeted
agents with focused radiation for pancreatic cancer.
Materials and Methods
Animal Xenografts
Female athymic nude mice (4 weeks old; Harlan Sprague-Dawley,
Madison, WI) were used in accordance with institutional guidelines
under approved protocols. The MiaPaCa-2 pancreas carcinoma cell
line stably transfected with the luciferase-aminoglycoside phospho-
transferase fusion gene under the control of the elongation factor
(EF)-1α promoter (MiaPaCa-2–ELN) was kindly provided by
Dr Ralph Graeser, ProQinase GMBH, Freiburg, Germany [11]. Mice
were anesthetized by intraperitoneal injection of 75 mg/kg ketamine
and 7.5 mg/kg xylazine before surgery and treatment. Subcutaneous
flank tumors were generated bilaterally by injection of 1 × 106
MiaPaCa-2–ELN cells in 100 μl of phosphate-buffered saline per
flank. Tumor dimensions and animal weights were measured twice
per week. Tumor volume was calculated according to the equation
for a prolate spheroid ((π/6) × (L × W 2)), where L and W are the
longer and shorter dimensions of the tumor, respectively. Tumor
growth inhibition (TGI) and tumor growth delay were determined
by reduction in volume, as previously described [12]. Orthotopic
pancreatic tumors were generated by injection of 1 to 2 × 106
MiaPaCa-2–ELN cells into the tail of the pancreas. Mice were killed
when moribund, if they experienced a change in body weight of
20% of pretreatment weight, or if tumor size/burden exceeded 10 times
the pretreatment volume.
Tumor Imaging
Small animal positron emission tomographic/computed tomo-
graphic (PET/CT; Philips Mosaic HP, Sunnyvale, CA) images of
overnight-fasted, anesthetized mice with orthotopic tumors were obtained
after intravenous (IV) injection of 10 MBq of 18F-fluorodeoxyglucose
with an uptake time of 60 minutes and static acquisition of 15 minutes.
Corresponding small animal CT images were acquired, fused, and
registered with PET images per standard protocol. Tumor regions of
interest (ROIs) were identified after calculating standardized uptake
values normalized to the liver, and tumor dimensions (length and width)
were recorded.
For BLI, anesthetized mice bearing subcutaneous flank or
orthotopic tumors were injected intraperitoneally with 150 mg/kg
of D-luciferin (Gold Biotechnology, St Louis, MO) and optically im-
aged after 10 minutes using the IVIS 100 (Xenogen Corp, Alameda,
CA). The pseudocolor image representing the spatial distribution of
detected photons was overlaid on a grayscale photographic image. An
ROI was created around the optical tumor image so that the lumi-
nescence at the edge of the circle was 5% of the peak intensity of that
region. Signal intensity was quantified within an identified ROI in
photons/second/squared centimeter/steradian (p/s/cm2/Sr) after a
10-second exposure using Living Image software (Xenogen Corp).
Statistical Analysis
Maximum cross-sectional length and width in the coronal plane of
PET-CT and BLI images (n = 8) were measured, used to calculate
area and volume, and correlated to pathologic tumor specimen at
necropsy, as described above, using Pearson correlation coefficient.
Nonlinear regression plots were used to describe the correlation be-
tween bioluminescent photon emission and caliper volume measure-
ments of tumors.
Luminescent Source Localization
A 5-mm-diameter glass bulb was filled with 5 × 105 MiaPaCa-2–
ELN cells, injected with D-luciferin and sutured to the tail of the
pancreas of an euthanized mouse (n = 6). The abdomen was sutured
closed, and the centroid of the bulb was identified in the following
ways: 1) an opaque fiducial placed on the skin surface of the mouse
to visually approximate its location or 2) two-dimensional (2D) sur-
face BLI. CBCT images of the mice were acquired on the SARRP to
localize the actual centroid of the bulb and coregistered with the two
methods described above. The radial distance between centroids was
then measured and compared.
Tumor Irradiation
Five days after tumor implantation, mice were imaged with 2D
bioluminescence and transported to the SARRP where CBCT images
of anesthetized mice were acquired. Using the guidance software util-
ity of the SARRP, BLI and CBCT images were coregistered by man-
ual fusion; the isocenter of the tumor was identified and aligned with
the central axis of the beam. Mice were irradiated with the SARRP
using 225 kV (peak) x-ray beams at a dose rate of 2.5 Gy/min using
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collimator of various diameters with a single anterior-posterior beam
under the guidance of CBCT. Mice bearing flank tumors were ran-
domized to receive one of the following treatments: 1) no radiation –
control; 2) 5 Gy × 1 fraction; 3) 5 Gy × 2 fractions, 1 fraction daily;
and 4) 5 Gy × 3 fractions, 1 fraction daily. The dose that resulted
in an intermediate level of tumor growth delay was identified and
selected for subsequent irradiation of orthotopic tumors.
Histologic and Immunofluorescent Staining
One hour after BLI-guided irradiation of orthotopic tumors, whole-
body perfusion fixation of anesthetized mice was performed using 4%
paraformaldehyde injection into the left ventricle per established protocol
[13]. Once perfusion was complete, the abdominal contents were pro-
cessed 1 of 2 ways. The entire abdomen with skin intact was separated
from the thorax and pelvis, so as to keep organs in their native position,
incubated in 30% sucrose for 24 hours, embedded in optimum cut-
ting temperature, and sectioned using a cryostat microtome at −20°C.
Alternatively, after perfusion fixation, the tumor specimen and sur-
rounding abdominal organs were individually dissected, placed in 4%
paraformaldehyde for 24 hours, paraffin embedded, and sectioned.
Immunofluorescent detection of γ-H2Ax was performed after per-
meabilization with 0.05% Triton in Tween-20 (Roche, Mannheim,
Germany) for 1 minute after deparaffinization with xylene and rehy-
dration with ethanol. Slides were steamed for 45 minutes at 95°C for
antigen retrieval, placed in 3% bovine serum albumin overnight, in-
cubated with mouse anti–phospho-histone H2Ax (Ser139; Cell Sig-
naling Technology, Danvers, MA), and followed by goat antimouse
Alexa Fluor 594 secondary antibody (Molecular Probes, Eugene, OR).
Nuclei were counterstained with 4′,6-diamidino-2-phenylindole
dihydrochloride solution (Invitrogen, Carlsbad, CA), and coverslips
were mounted with Vectashield (Vector Laboratories, Peterborough,
United Kingdom). The edges of coverslips were sealed with clear nail
polish. Imaging was performed in the dark with confocal microscopy
equipped with filter blocks for excitation of red, green, and blue fluo-
rescence. Individual nuclei and γ-H2Ax-foci were counted by a single
operator to minimize variability. Six separate regions within each ana-
lyzed specimen of irradiated and unirradiated tissue containing a min-
imum of 40 cells were identified, and data were reported as the average
sum of foci divided by average number of nuclei.
Results
Correlation of Bioluminescence with PET/CT and
Tumor Volume
As an initial experiment, subcutaneous bioluminescent xenografts
were used to assess the limits of detection and relationship to physical
volume of tumors. Injection of MiaPaCa-2–ELN cells into the bilat-
eral flanks of athymic mice resulted in 100% engraftment and growth
of tumors, which were subsequently imaged for bioluminescence and
measured with calipers biweekly. There was significant linear correla-
tion (R = 0.8984) between bioluminescent photon counts and mea-
sured tumor volume as noted by linear regression analysis (Figure 1A).
In addition, mean photon counts measured as a function of time were
normalized to baseline values obtained 3 days after tumor implantation
(noted as day 0). Photon counts increased linearly as a function of time
until approximately day 20 when values began to plateau after an
approximate 10-fold increase in normalized luminescence (Figure 1B).
As a result, a 10× increase in relative tumor burden, as measured by BLI,
was used as an end point for subsequent experiments.
In an attempt to validate BLI as a molecular imaging surrogate for
viable tumor detection and assessment of physical tumor size, we cor-
related tumor BLI to PET/CT and pathologic measurements at nec-
ropsy. Orthotopically injected MiaPaCa-2–ELN tumors were
engrafted into the pancreatic tail in 100% of specimens without any
associated morbidity or mortality. Tumors were detectable by both
BLI and PET/CT a minimum of 3 days after implantation and were
formally assessed at days 5 and 10 by all three modalities. Using Pearson
coefficient, greatest length, width, and cross-sectional area of the 95%
bioluminescent image was correlated to that of PET/CT and pathologic
specimen (Table 1). There was excellent length and width correlation
between BLI and PET/CT (R = 0.94 and R = 0.96, respectively).
Whereas both BLI and PET/CT tumor lengths correlated moderately
well with necropsy specimen (R = 0.80 and R = 0.87, respectively), they
did not correlate well with regard to tumor widths (R = 0.64 and R =
0.68, respectively). Comparison of cross-sectional area also showed
good correlation among all three modalities (Table 1). Bioluminescence
and PET/CT were equally sensitive in detecting the presence of meta-
static lesions from primary orthotopic tumors as confirmed pathologically
at time of necropsy. Most metastases were identified macroscopically in
the liver, spleen, and lung.
Figure 1. BLI accurately predicts tumor volume (A). Mean photon counts (p/s/cm2/Sr) of MiaPaCa-2–ELN heterotopic tumors of varying
sizes correlated well with measured tumor volume as noted by linear regression analysis (R = 0.8984; A). Normalized luminescence
of pancreatic tumors was determined as a function of time and shows a relatively linear increase in signal up to 10-fold after which
plateaued growth was noted (B).
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Luminescent Source Localization
We then attempted to determine whether the visually perceived cen-
troid of the bioluminescent image was representative of the physical
tumor centroid identified on CBCT using an orthotopically placed,
fixed-size source of luminescence. These data would facilitate accurate
placement of the radiation beam isocenter and aid in determining the
potential animal positioning and setup error associated with fusion of
the two imaging modalities (n = 4/group). A significant deviation of
5.8 mm was noted between the skin surface marker and the center
of the bulb as identified on CBCT. This deviation margin decreased
to 3.5 mm when 2D offline BLI was fused to the CBCT image. As
a result, 2D bioluminescent images were used for tumor localization
and image guidance with a radial margin of 4 mm applied to the tumor
volume to create a pseudo-“planning target volume” (PTV; Figure 2).
To cover this volume, average collimator sizes used ranged from 10 to
15 mm in diameter when a 4-mm radial margin was applied to the
gross tumor volume as determined from the 95% bioluminescent
image fused to the CBCT image.
Determining Tumor Response to Irradiation
Using a 10-fold increase in normalized luminescence as an end
point (as previously determined), subcutaneous flank tumors were
left untreated or treated with varying radiation doses to identify the
dose that would result in an intermediate, yet significant, level of TGI
without significant toxicity (Figure 3). Irradiation with 5 Gy, 5 Gy ×
2 fractions, and 5 Gy × 3 fractions led to growth delays of 31, 57.5,
and 60 days, respectively, relative to untreated controls (n = 4/group,
P < .05). Whereas growth delays seen with cumulative doses of 10 and
15 Gy were significantly longer compared to the 5-Gy treatment arm
and untreated controls (P < .05), there was no significant difference
between tumors treated with a total of 10 or 15 Gy. As a result, 5 Gy ×
1 was selected as an intermediate, yet significant dose level for all
subsequent orthotopic experiments. Of note, none of the irradiated
mice experienced treatment-related morbidity or mortality within
2 weeks of treatment irrespective of the dose.
Tumor Targeting Accuracy
Using 2D-BLI fused offline to CBCT for tumor localization and
image guidance as described previously, a single fraction of 5 Gy × 1
was delivered to orthotopic tumors using an anterior-posterior beam.
Accurate targeting of the tumor was confirmed through identification
and 2D localization of p-ATM and γ-H2Ax foci, which correlated to
radiation-induced DNA damage and sites of repair. Coronal abdominal
sections were generated orthogonal to the central beam axis to confirm
irradiation of the entire tumor and general sparing of neighboring
organs. This was more clearly identified through dissection and γ-H2Ax
staining of individual organs (Figure 4A). The pancreatic tumor
contained significantly more foci per cell (14.5) on average than the
liver (0.31), greater (11.5) and lesser curvature (0.11) of the stomach,
spleen (0.1), and unirradiated control (0.175; Figure 4B; P < .05). The
Figure 2. Radiation treatment planning and delivery to orthotopic
pancreatic tumors. (A) Coronal CBCT image of anesthetized
mouse obtained on the SARRP platform showing bony anatomy
without clear ability to identify pancreatic tumor. (B) Offline bio-
luminescent coronal image of anesthetized mouse seen in A.
Checkerboard fusion of images from A and B aligned to match
external animal contour and identifiable internal anatomy show-
ing excellent registration (C). (D) Double-exposure radiographs
obtained in the treatment position on the SARRP identifying the
radiation portal and confirming the area to be irradiated with 5 Gy
in a single fraction (D).
Figure 3. Radiation dose-response curve of heterotopic tumors.
MiaPaCa-2–ELN flank tumors irradiated with 5, 10, or 15 Gy in 5-Gy
daily fractions and assessed longitudinally show equal levels of
significant inhibition with cumulative doses of 10 and 15 Gy and
an intermediate level of growth inhibition with 5 Gy relative to un-
treated controls.
Table 1. Pearson Correlation Coefficient of Orthotopic Tumor Measurements.
Measurement Method Measurement Type Correlation 95% CI P
BLI vs PET/CT Length 0.94 0.65-0.99 .002*
BLI vs necropsy Length 0.80 0.11-0.97 .032*
PET vs necropsy Length 0.87 0.33-0.98 .011*
BLI vs PET/CT Width 0.96 0.73-0.99 .001*
BLI vs necropsy Width 0.64 0.22-0.94 .122
PET vs necropsy Width 0.68 0.14-0.95 .090
BLI vs PET/CT Area 0.97 0.78-10.0 .001*
BLI vs necropsy Area 0.79 0.09-0.97 .035*
PET vs necropsy Area 0.83 0.19-0.97 .022*
CI indicates confidence interval.
*P < .05.
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transverse colon adjacent to the pancreatic tumor was calculated to
have 12.2 γ-H2Ax foci per cell, which was not significantly different.
Identification of the irradiated regions was further confirmed by p-ATM
staining of individual organs, the patterns of which strongly correlated
with those described above (data not shown).
Bioluminescence Monitoring of Radiation-Induced Orthotopic
Tumor Growth Inhibition
After BLI-guided irradiation of orthotopic tumors (5 Gy × 1),
mice were longitudinally monitored for TGI relative to untreated
controls. At 30 days after treatment, irradiated tumors had a signif-
icantly lower mean photon emission of 7.1 × 109 p/s/cm2/Sr com-
pared to unirradiated tumors (2.1 × 1010 p/s/cm2/Sr), representing a
relative 2.97-fold inhibition of growth (Figure 5F ). This was also
confirmed pathologically at time of necropsy by measurement of
the same tumors revealing a significant 3.5-fold decrease in the vol-
ume of treated relative to untreated tumors (Figure 5C ; P < .05).
Finally, using the same end point of a 10-fold increase in normalized
tumor bioluminescence, mice were followed longitudinally, and a
significant tumor growth delay of 24 days was observed with the
irradiated (5 Gy × 1) mice relative to untreated controls (n = 4/
group; P < .05; Figure 5G ).
Discussion
The purpose of this study was to develop a biologically and clinically
relevant radiation research model to facilitate preclinical testing of
experimental therapeutics and sensitizers for the treatment of pan-
creatic cancer. Specifically, our goals were to apply the SARRP to
a bioluminescent, orthotopic xenograft model to noninvasively: 1)
allow identification of tumors and tumor burden before initiating
therapy, thereby eliminating a potentially unidentifiable variable asso-
ciated with randomization; 2) facilitate image-guided focal radiation
therapy; and 3) normalization of tumor burden and longitudinal
assessment of treatment response. We chose to use an orthotopic
xenograft tumor model that closely mimicked the clinical presentation
of pancreatic cancer patients and allowed tumors to grow in their native
microenvironment. Indeed, limiting studies of potentially therapeutic
agents to nonrepresentative preclinical models may provide an inaccu-
rate profile of treatment efficacy and can have disappointing conse-
quences when the agent is subsequently tested in the clinical setting
[14]. Recent studies have shown that implantation of tumor cells
ectopically versus orthotopically results in tumors with varying meta-
static potential [15]. More specific to our study, Nakamura et al.
[16] have shown a significant difference in gene expression patterns
of cell line–derived orthotopic pancreatic tumors relative to the same
tumors growing ectopically, thus highlighting the significant influence
of the orthotopic microenvironment. A potential criticism of our study
is the use of immortalized cell lines, albeit human and well character-
ized, which may or may not faithfully recapitulate human pancreatic
cancer. Rubio-Viquera et al. [17] postulate that the in vitro adaptation
of such lines may result in significant genetic alterations before ortho-
topic implantation, thus potentially altering the tumorigenic process. In
our study, orthotopic tumors were found to eventually become not
only locally invasive but also metastatic based on the anticipated hema-
togenous patterns of spread of disease. The inherent benefit of using
immortalized lines is the ability to endogenously express luciferase,
Figure 4. Staining with 4′,6-diamidino-2-phenylindole dihydrochloride and γ-H2Ax of abdominal organ dissected after focused abdominal
radiation per Figure 3 shows intense colocalized staining of pancreatic tumor, as well as transverse colon and greater curvature of stomach,
which were partly within the radiation field (A; original magnification, ×40). Other abdominal organs, including liver, lesser curvature of the
stomach, and spleen, showminimal to no γ-H2Ax staining (A). Quantification of γ-H2Ax foci in A reported as the average sum of foci divided
by the average number of nuclei in areas containing a minimum of 40 cells showing significantly higher quantities of staining in the
pancreatic tumor relative to the liver, greater and lesser curvature of the stomach, spleen, and unirradiated control (B; P < .05).
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which is not technically feasible with the use of primary human tumor
explants. However, future studies are investigating the application of
orthotopic xenografts established directly from patients with pancreatic
cancer [17].
To our knowledge, a limited number of preclinical models evalu-
ating irradiation of orthotopic tumor xenografts have been reported
[18,19]. With the exception of the recent report by Lee et al. [9],
none exist for pancreatic cancer. In addition, these studies used rela-
tively imprecise methods of tumor targeting and radiation delivery,
which certainly raises the possibility of not only missing the target,
but also potentially overtreating nearby normal tissues, both of which
could alter or confound the study’s outcomes and limit the applica-
bility of these data to contemporary radiation therapy used in the
clinic. On the basis of these considerations, we focused on validating
BLI as a noninvasive, facile means of providing image guidance for
directing RT, and longitudinally monitoring tumors and subsequent
response to therapy. Bioluminescence served as an accurate surrogate
for pathologic tumor volume. In addition, when tumors were assessed
longitudinally as a function of time, a linear increase in bioluminescent
signal relative to tumor growth was noted until a plateau was reached.
The plateau can likely be explained by the variable areas of hypoxia
found within the larger tumors combined with the dependence of the
luciferase reaction on oxygen [20]. On the basis of these data, we were
confidently able to use BLI for longitudinal monitoring of tumors in the
same animal over time, thereby eliminating the need for a substantial
number of animals and facilitating accurate assessment of normalized
tumor growth over time. Indeed, the costs, inefficiency, and potential
lack of accuracy associated with invasive monitoring of treatment effect
are an inherent criticism of many prospective preclinical studies.
Validation of BLI as a functional imaging surrogate was obtained
through comparison with PET/CT. A major limitation of CBCT is its
inability to adequately identify soft tissue tumors in the thorax and
abdomen due to lack of contrast at lower imaging doses. Clinically,
PET/CT is increasingly being used as the criterion standard for
functional tumor imaging, thereby allowing accurate tumor staging
and assessment of treatment response [21]. In addition, given the
Figure 5. Longitudinal monitoring of bioluminescent orthotopic pancreatic tumors treated with or without 5 Gy of BLI-guided radiation
shows treated tumors with a significantly lower tumor burden confirmed by pathologic (C) and mean photon emission mean (F) relative
to respective controls. This is graphically depicted in the same animals in A and B and in D and E. When followed over time, irradiated
tumors (▪) showed a significant growth inhibition of 24 days compared to untreated tumors (•) using a 10× increase in tumor burden as
an end point (G).
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combination of functional and anatomic information provided in a
single set of fused images, PET/CT is increasingly being used to more
accurately guide radiation treatment planning in the clinic [22]. How-
ever, preclinical use of this modality is limited because of the time re-
quired per scan, the cost, as well as the potential for distress to the
animals during prolonged sedation. Fusion of molecular optical imag-
ing, such as BLI, with CT is done under the assumption that the func-
tional image is an accurate spatial representation of the structural image.
We validated this by correlating the BLI centroid with that of a focal,
rigid radio-opaque surrogate of a tumor. The radial distances approxi-
mated each other quite well and dictated the need for a tumor margin
expansion of approximately 4 mm to account for potential setup errors.
Indeed, improved tumor localization obviates the need for larger irra-
diation fields and also helps minimize potentially confounding added
toxicities, especially in abdominal malignancies such as pancreatic
cancer. However, minimizing margins may also risk missing some of
the tumor target. Similar to other functional imaging modalities, bio-
luminescence resulted in poor spatial resolution but provided an
adjunctive means of identifying and targeting viable tumor when com-
bined with CT images. Identification of double-stranded DNA damage
and repair through p-ATM and γ-H2Ax staining confirmed our ability
to accurately and repeatedly target the tumor while minimizing irra-
diation of normal tissues and associated toxicity. Given the lack of
dosimetric treatment planning similar to that used in the clinic, γ-H2Ax
quantitation was used as a potential surrogate biodosimeter. Previous
studies have quantitated in vivo γ-H2Ax immunofluorescence and
accurately correlated these levels to estimated radiation dose distribu-
tions [23]. Similarly in our study, normal organs at risk near the tar-
geted tumor had comparable levels of γ-H2Ax foci. As a result, we
assumed that the full dose was received by these regions comparable
to the clinical setting when pancreatic tumors are irradiated and por-
tions of the duodenum, small bowel, and liver receive close to the pre-
scribed full dose.
Potential limitations of our study included the use of 2D optical
imaging and offline methods for fusion to CT where the animal is
transported between imaging modalities. At present, nonnegligible
uncertainty exists with this method, which is potentially reduced with
fusion of the optical image and on-board CBCT to guide animal
placement. We have also used a single orthogonally directed beam
as a simple model of irradiating the fused BLI-CBCT tumor target,
which was sufficient for accurate targeting and more efficient for
throughput treatment. Indeed, achieving a fully conformal 3D treat-
ment volume using multiple radiation beams would be predicated on
the successful fusion of a complementary 3D bioluminescent tomo-
graphic image and appropriate treatment planning. These studies are
currently on going in our laboratory. Our initial radiation experiments
attempted to identify the dose and fractionation scheme that led to an
intermediate level of tumor growth delay without causing excessive
treatment-related toxicities. During a course of 5 weeks, radiation-
induced tumor growth inhibition was readily predicted by BLI and also
confirmed pathologically. Bioluminescent disease progression was able
to presage development of local symptoms (ascites, palpable tumor
growth), thereby suggesting its use as a potential surrogate for estimat-
ing local tumor control and disease-free survival [24].
In summary, our studies confirm the ability to accurately and effi-
ciently deliver RT to orthotopic pancreatic tumors in mice using
a combination of molecular (BLI) and anatomic (CBCT) imaging
while minimizing the dose to the surrounding normal tissues. BLI
is a cost-effective surrogate for PET. It also allows for normalization
of pretreatment tumor burden and quantitative, noninvasive moni-
toring of tumor progression in real time. This standardized preclinical
RT platform provides the ability to closely mimic contemporary
human RT and facilitate rapid, high-throughput evaluation of poten-
tial radiation sensitizers for pancreas cancer treatment.
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